Breyer, Johannes and Eckstein, Markus and Sikic, Danijel and Wezel, Felix and Roghmann, Florian and Brehmer, Mirco and Wirtz, Ralph M. and Jarczyk, Jonas and Erben, Philipp and Bahlinger, Veronika and Goldschmidt, Franziska and Fechner, Guido and Chen, Jack and Paxinos, Ellen and Bates, Michael and Haas, Maximilian and Zengerling, Friedemann and Bolenz, Christian and Burger, Maximilian and Hartmann, Arndt and Kriegmair, Maximilian C. (2023) Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial). SCIENTIFIC REPORTS, 13 (1): 15437. ISSN 2045-2322,
Full text not available from this repository. (Request a copy)Abstract
To determine whether Xpert bladder cancer monitor, a noninvasive PCR-based biomarker test, can predict the need for 2nd transurethral resection of the bladder (TURB) better than clinical assessment. Patients scheduled for TURB were prospectively screened. After initial TURB, patients were assigned to 2nd TURB or follow-up cystoscopy at 3 months (FU) by clinicians' discretion. Central urine cytology and Xpert monitor tests were performed prior to the 1st TURB and 2nd TURB or FU, respectively. Statistical analysis to compare clinical assessment and Xpert monitor comprised sensitivity (SENS), specificity (SPEC), NPV and PPV. Of 756 screened patients, 171 were included (114 with 2nd TURB, 57 with FU). Residual tumors were detected in 34 patients who underwent 2nd TURB, and recurrent tumors were detected in 2 patients with FU. SENS and SPEC of Xpert monitor were 83.3% and 53.0%, respectively, PPV was 32.6% and NPV was 92.1%. Clinical risk assessment outperformed Xpert monitor. In patients with pTa disease at initial TURB, Xpert monitor revealed a NPV of 96%. Xpert monitor was not superior than clinical assessment in predicting the need for 2nd TURB. It might be an option to omit 2nd TURB for selected patients with pTa disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | QUALITY-OF-LIFE; TRANSURETHRAL RESECTION; UROTHELIAL CARCINOMA; RECURRENCE; PROGRESSION; IMPACT; TUMOR; RATES; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Mar 2024 14:21 |
| Last Modified: | 19 Mar 2024 14:21 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60361 |
Actions (login required)
 |
View Item |
